Perrigo Debt to Equity Ratio 2010-2025 | PRGO
Perrigo Debt/Equity Ratio Historical Data | |||
---|---|---|---|
Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
2025-03-31 | $5.40B | $4.36B | 1.24 |
2024-12-31 | $5.33B | $4.32B | 1.23 |
2024-09-30 | $6.64B | $4.57B | 1.45 |
2024-06-30 | $5.85B | $4.55B | 1.29 |
2024-03-31 | $5.95B | $4.69B | 1.27 |
2023-12-31 | $6.04B | $4.77B | 1.27 |
2023-09-30 | $6.02B | $4.74B | 1.27 |
2023-06-30 | $6.12B | $4.85B | 1.26 |
2023-03-31 | $6.12B | $4.83B | 1.27 |
2022-12-31 | $6.18B | $4.84B | 1.28 |
2022-09-30 | $6.08B | $4.60B | 1.32 |
2022-06-30 | $6.07B | $4.85B | 1.25 |
2022-03-31 | $5.29B | $5.11B | 1.04 |
2021-12-31 | $5.27B | $5.15B | 1.02 |
2021-09-30 | $5.73B | $5.18B | 1.11 |
2021-06-30 | $5.72B | $5.51B | 1.04 |
2021-03-31 | $5.77B | $5.56B | 1.04 |
2020-12-31 | $5.83B | $5.66B | 1.03 |
2020-09-30 | $5.76B | $5.82B | 0.99 |
2020-06-30 | $6.22B | $5.91B | 1.05 |
2020-03-31 | $5.61B | $5.79B | 0.97 |
2019-12-31 | $5.50B | $5.80B | 0.95 |
2019-09-30 | $5.55B | $5.76B | 0.96 |
2019-06-30 | $5.70B | $5.73B | 1.00 |
2019-03-31 | $5.42B | $5.70B | 0.95 |
2018-12-31 | $5.32B | $5.67B | 0.94 |
2018-09-30 | $5.28B | $5.66B | 0.93 |
2018-06-30 | $5.33B | $5.90B | 0.90 |
2018-03-31 | $5.43B | $6.21B | 0.88 |
2017-12-31 | $5.46B | $6.17B | 0.89 |
2017-09-30 | $5.80B | $6.04B | 0.96 |
2017-06-30 | $5.71B | $6.08B | 0.94 |
2017-03-31 | $7.91B | $6.07B | 1.30 |
2016-12-31 | $7.91B | $5.96B | 1.33 |
2016-09-30 | $8.41B | $7.48B | 1.12 |
2016-06-30 | $9.24B | $9.05B | 1.02 |
2016-03-31 | $9.77B | $9.73B | 1.01 |
2015-12-31 | $9.24B | $10.11B | 0.92 |
2015-09-30 | $8.97B | $10.73B | 0.84 |
2015-06-30 | $9.06B | $10.66B | 0.85 |
2015-03-31 | $6.60B | $9.59B | 0.69 |
2014-12-31 | $6.75B | $9.72B | 0.69 |
2014-09-30 | $5.06B | $8.72B | 0.58 |
2014-06-30 | $5.19B | $8.69B | 0.60 |
2014-03-31 | $5.18B | $8.56B | 0.61 |
2013-12-31 | $5.21B | $8.50B | 0.61 |
2013-09-30 | $3.04B | $2.47B | 1.23 |
2013-06-30 | $3.02B | $2.33B | 1.29 |
2013-03-31 | $2.27B | $2.23B | 1.02 |
2012-12-31 | $2.19B | $2.11B | 1.04 |
2012-09-30 | $2.15B | $1.97B | 1.10 |
2012-06-30 | $2.17B | $1.85B | 1.17 |
2012-03-31 | $2.27B | $1.77B | 1.28 |
2011-12-31 | $2.31B | $1.63B | 1.42 |
2011-09-30 | $1.97B | $1.54B | 1.28 |
2011-06-30 | $1.66B | $1.53B | 1.08 |
2011-03-31 | $1.61B | $1.43B | 1.13 |
2010-12-31 | $1.63B | $1.31B | 1.24 |
2010-09-30 | $1.57B | $1.21B | 1.30 |
2010-06-30 | $2.02B | $1.09B | 1.84 |
2010-03-31 | $1.43B | $1.06B | 1.35 |
2009-12-31 | $1.47B | $0.99B | 1.49 |
2009-09-30 | $1.44B | $0.96B | 1.50 |
2009-06-30 | $1.61B | $0.92B | 1.75 |
2009-03-31 | $1.53B | $0.84B | 1.82 |
Sector | Industry | Market Cap | Revenue |
---|---|---|---|
Medical | Medical Products Manufacturing | $3.746B | $4.373B |
Perrigo Co. plc, with a diversified revenue stream, sells infant formulas for the store brand market, generic extended topical prescription (Rx) products and specialty pharmaceutical drugs. It's focusing on self-care products as part of its transformation into a self-care company from a healthcare company. The company divested its Rx segment to Altaris Capital Partners. The company completed its transformation to a consumer self-care company by reconfiguring the portfolio through the divestiture of RX business. Currently, the company has 2 reporting segments. Consumer Self Care Americas (CSCA): The segment comprises the U.S., Mexico and Canada CHC business, including OTC, contract manufacturing, infant formula and animal health categories. Consumer Self Care International?(CSCI): The segment comprises the branded consumer healthcare (BCH) segment mainly in Europe and the company's consumer-focused businesses in the UK and Australia. This segment includes UK liquids licensed products business. |
Stock Name | Country | Market Cap | PE Ratio |
---|---|---|---|
Abbott Laboratories (ABT) | United States | $237.401B | 28.55 |
Boston Scientific (BSX) | United States | $145.814B | 36.50 |
Stryker (SYK) | United States | $145.229B | 30.37 |
EssilorLuxottica (ESLOY) | France | $130.605B | 0.00 |
Medtronic (MDT) | Ireland | $113.492B | 16.09 |
Lonza Group Ag (LZAGY) | Switzerland | $51.916B | 0.00 |
Haleon (HLN) | United Kingdom | $49.556B | 28.23 |
ResMed (RMD) | United States | $36.981B | 27.78 |
Agilent Technologies (A) | United States | $33.778B | 22.02 |
GE HealthCare Technologies (GEHC) | United States | $33.476B | 15.89 |
Terumo (TRUMY) | Japan | $27.213B | 35.35 |
Koninklijke Philips (PHG) | Netherlands | $22.201B | 15.96 |
Insulet (PODD) | United States | $21.367B | 83.87 |
Zimmer Biomet Holdings (ZBH) | United States | $18.451B | 11.85 |
Baxter (BAX) | United States | $16.093B | 12.02 |
Smith & Nephew SNATS (SNN) | United Kingdom | $13.187B | 0.00 |
Sunny Optical Technology (SNPTF) | China | $9.076B | 0.00 |
Demant (WILYY) | Denmark | $8.854B | 0.00 |
Bio-Rad Laboratories (BIO) | United States | $6.325B | 22.01 |
Lantheus Holdings (LNTH) | United States | $5.545B | 13.99 |
Prestige Consumer Healthcare (PBH) | United States | $4.207B | 18.80 |
Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
Haemonetics (HAE) | United States | $3.428B | 15.61 |
ICU Medical (ICUI) | United States | $3.258B | 24.02 |
Envista Holdings (NVST) | United States | $3.198B | 26.58 |
GN Store Nord (GNNDY) | Denmark | $2.319B | 19.20 |
QuidelOrtho (QDEL) | United States | $2.021B | 13.90 |
LeMaitre Vascular (LMAT) | United States | $1.839B | 41.10 |
AtriCure (ATRC) | United States | $1.600B | 0.00 |
Acuren (TIC) | United States | $1.308B | 0.00 |
Neogen (NEOG) | United States | $1.220B | 15.61 |
AdaptHealth (AHCO) | United States | $1.187B | 12.05 |
BioLife Solutions (BLFS) | United States | $1.107B | 0.00 |
Green Thumb Industries (GTBIF) | United States | $1.061B | 23.86 |
Phibro Animal Health (PAHC) | United States | $0.993B | 12.70 |
Kestra Medical Technologies (KMTS) | United States | $0.963B | 0.00 |
InMode (INMD) | Israel | $0.888B | 8.95 |
CeriBell (CBLL) | United States | $0.657B | 0.00 |
Evolus (EOLS) | United States | $0.656B | 0.00 |
Capricor Therapeutics (CAPR) | United States | $0.637B | 0.00 |
Owens & Minor (OMI) | United States | $0.616B | 5.11 |
Maravai LifeSciences Holdings (MRVI) | United States | $0.576B | 0.00 |
Curaleaf Holdings (CURLF) | Canada | $0.547B | 0.00 |
Valneva SE (VALN) | France | $0.523B | 0.00 |
Tilray Brands (TLRY) | Canada | $0.419B | 0.00 |
Surmodics (SRDX) | United States | $0.416B | 0.00 |
SNDL (SNDL) | Canada | $0.355B | 0.00 |
VAREX IMAGING (VREX) | United States | $0.351B | 12.92 |
Aurora Cannabis (ACB) | Canada | $0.342B | 60.90 |
SEMPERIT AG HLD (SEIGY) | Austria | $0.329B | 0.00 |
Canopy Growth (CGC) | Canada | $0.281B | 0.00 |
Viemed Healthcare (VMD) | United States | $0.268B | 22.60 |
Sanuwave Health (SNWV) | United States | $0.265B | 0.00 |
Cerus (CERS) | United States | $0.262B | 0.00 |
ZimVie (ZIMV) | United States | $0.258B | 11.75 |
Sanara MedTech (SMTI) | United States | $0.255B | 0.00 |
Cresco Labs (CRLBF) | United States | $0.251B | 0.00 |
Quanterix (QTRX) | United States | $0.240B | 0.00 |
OraSure Technologies (OSUR) | United States | $0.219B | 0.00 |
Biote (BTMD) | United States | $0.216B | 6.08 |
Brainsway (BWAY) | Israel | $0.216B | 57.10 |
TriSalus Life Sciences (TLSI) | United States | $0.208B | 0.00 |
Omeros (OMER) | United States | $0.208B | 0.00 |
Organigram Global (OGI) | Canada | $0.197B | 0.00 |
High Tide (HITI) | Canada | $0.189B | 0.00 |
Utah Medical Products (UTMD) | United States | $0.186B | 15.18 |
Verano Holdings (VRNOF) | United States | $0.180B | 0.00 |
Exagen (XGN) | United States | $0.149B | 0.00 |
Vireo Growth (VREOF) | United States | $0.143B | 0.00 |
FitLife Brands (FTLF) | United States | $0.134B | 16.51 |
Jin Medical (ZJYL) | China | $0.109B | 0.00 |
MacroGenics (MGNX) | United States | $0.098B | 0.00 |
Veru (VERU) | United States | $0.096B | 0.00 |
Oramed Pharmaceuticals (ORMP) | United States | $0.092B | 0.00 |
Fonar (FONR) | United States | $0.090B | 11.60 |
Quipt Home Medical (QIPT) | United States | $0.089B | 0.00 |
TerrAscend (TSNDF) | Canada | $0.077B | 0.00 |
Agape ATP (ATPC) | $0.077B | 0.00 | |
InterCure (INCR) | Israel | $0.067B | 0.00 |
Cytosorbents (CTSO) | United States | $0.067B | 0.00 |
Apyx Medical (APYX) | United States | $0.065B | 0.00 |
Zynex (ZYXI) | United States | $0.063B | 0.00 |
ImmuCell (ICCC) | United States | $0.058B | 0.00 |
Jushi Holdings (JUSHF) | United States | $0.057B | 0.00 |
Modular Medical (MODD) | United States | $0.043B | 0.00 |
Nephros (NEPH) | United States | $0.043B | 57.29 |
United-Guardian (UG) | United States | $0.038B | 13.02 |
Rockwell Medical (RMTI) | United States | $0.033B | 0.00 |
Cellectar Biosciences (CLRB) | United States | $0.020B | 0.00 |
Allurion Technologies (ALUR) | United States | $0.019B | 0.00 |
Safety Shot (SHOT) | United States | $0.018B | 0.00 |
Flora Growth (FLGC) | United States | $0.018B | 0.00 |
INLIF (INLF) | $0.013B | 0.00 | |
Meihua Medical Technologies (MHUA) | China | $0.012B | 0.00 |
Trinity Biotech (TRIB) | Ireland | $0.012B | 0.00 |
Innovative Eyewear (LUCY) | United States | $0.008B | 0.00 |
IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
Senestech (SNES) | United States | $0.005B | 0.00 |
GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
Akanda (AKAN) | Canada | $0.002B | 0.00 |
Sharps Technology (STSS) | United States | $0.000B | 0.00 |
InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |